PAX7 shows high expression levels in breast cancer (BRCA), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), gastric adenocarcinoma (STAD), and thyroid cancer (THCA), while also being highly expressed in prostate adenocarcinoma (PRAD) and glioma (GBM). Here, PAX7 is linked to invasive breast carcinoma.